楼主: nikulawick
3714 9

[外行报告] 20140320花旗银行关于中国医药行业的深度分析报告 [推广有奖]

  • 1关注
  • 1粉丝

副教授

13%

还不是VIP/贵宾

-

威望
0
论坛币
13813 个
通用积分
1.8727
学术水平
8 点
热心指数
11 点
信用等级
8 点
经验
21132 点
帖子
154
精华
0
在线时间
1198 小时
注册时间
2008-8-22
最后登录
2022-3-18

相似文件 换一批

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币
新鲜出炉的花旗银行医药行业报告,全英文40页深度。
Dissecting Change: Structural Shifts to Re-draw Landscape
 Winners From Upcoming Value Chain Shift — China’s healthcare sector is on
the cusp of structural changes that will significantly recast the value chain. Our
deep-dive analysis suggests more market-based healthcare provision will open up
major opportunities for healthcare services providers and innovative pharma and
devices players. We also studied the evolution of health insurance in developed
markets and envision the likelihood of a multi-payer system where the government
may open the commercial insurance market. We revisit our investment framework
to evaluate likely winners upstream and downstream in the healthcare sector, and
now prefer Fosun Pharma as a focus stock for 2014 (see upgrade note).
 Services Sector the Focus — Market focus and capital deployment will shift more
towards healthcare services companies (currently ~2% of market cap of HK-listed
Chinese healthcare companies vs. 13% in the US), in our view, driven by hospital
privatization and the emergence of the services sector. New business models to be
potential beneficiaries are: 1) private healthcare providers, such as private hospitals
and health check-up centers; and 2) 3rd-party testing labs. (Sector roadmap inside.)
 Value Capture Through R&D — As the pharma segment becomes more market
based, and with the patent cliff cycle slowing in 2017-18, pharmas now focused on
dominating sales channels and first-to-market generics will gradually look to drive
sales through R&D and drugs innovation. Device companies will need to make a
similar shift to in-house product innovation to stay competitive. Also likely to emerge
is a subsector that converges healthcare services, internet and mobile technologies.

二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝

关键词:中国医药行业 中国医药 医药行业 深度分析 分析报告 花旗银行 中国医药 行业

20140320-Citi-China Healthcare.pdf

459.79 KB

需要: 5 个论坛币  [购买]

本帖被以下文库推荐

沙发
pegagao 发表于 2014-3-27 01:36:20 |只看作者 |坛友微信交流群
看看

使用道具

藤椅
jiubuxing 发表于 2014-4-2 11:47:02 |只看作者 |坛友微信交流群
十分支持,看好楼主,谢谢

使用道具

板凳
牛毛77 发表于 2014-4-2 13:14:25 |只看作者 |坛友微信交流群
真是及时雨~~感谢楼主!

使用道具

报纸
mybbmmyynn 发表于 2014-5-28 11:07:02 |只看作者 |坛友微信交流群
为啥显示说内部错误,无法显示此内容?

使用道具

地板
mybbmmyynn 发表于 2014-5-28 11:09:34 |只看作者 |坛友微信交流群
感谢楼主!

使用道具

7
boysky2 发表于 2014-6-5 11:50:01 |只看作者 |坛友微信交流群
谢谢楼主,好东西

使用道具

8
freeqxd 发表于 2014-7-16 14:29:37 |只看作者 |坛友微信交流群
Thanks for your sharing

使用道具

9
wangningning2 发表于 2015-4-6 10:57:41 |只看作者 |坛友微信交流群
谢谢楼主

使用道具

10
wikimiao 学生认证  发表于 2015-11-19 21:50:40 |只看作者 |坛友微信交流群
感谢楼主分享!

使用道具

您需要登录后才可以回帖 登录 | 我要注册

本版微信群
加JingGuanBbs
拉您进交流群

京ICP备16021002-2号 京B2-20170662号 京公网安备 11010802022788号 论坛法律顾问:王进律师 知识产权保护声明   免责及隐私声明

GMT+8, 2024-5-17 23:50